Abstract：
Dupilumab is a fully humanized IgG4 monoclonal antibody, inhibiting IL-4 and IL-13 signaling, which are the main cytokines involved in type 2 inflammatory diseases. Its introduction was a breakthrough in the treatment of moderate-to-severe atopic dermatitis, but it is also used in other inflammatory diseases, including asthma, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis. Recent advances in the understanding of inflammatory pathways have revealed that Th2-type inflammation is involved in a wider range of diseases than previously thought. The aim of our review is to examine off-label therapeutic indications of dupilumab, including bullous dermatoses (pemphigus, bullous pemphigoid) and alopecia areata, and to investigate its potential applications in cancer patients on anti-PD1 therapy.
摘要：
Dupilumab是一种完全人源化的IgG4单克隆抗体，抑制IL-4和IL-13信号，是参与2型炎症性疾病的主要细胞因子。它的推出是中重度特应性皮炎治疗的突破,但它也用于其他炎症性疾病，包括哮喘,嗜酸性粒细胞性食管炎和慢性鼻-鼻窦炎伴鼻息肉。对炎症途径的理解的最新进展表明，Th2型炎症涉及比以前认为的更广泛的疾病。我们审查的目的是检查dupilumab的标签外治疗适应症，包括大疱性皮肤病（天疱疮，大疱性类天疱疮）和斑秃，并探讨其在抗PD1治疗癌症患者中的潜在应用。
